10月20日，施贵宝盘中上涨3.46%，报60.34美元/股，成交额4237.42万美元。
最新催化来自机构观点上修预期。市场消息显示，有机构预计公司第三季度收入将超过市场一致预期，驱动因素包括Eliquis、Revlimid等成熟产品销售强于预期，以及增长产品放量。
不过，近期卖方也下调了公司目标价至60美元，显示市场对其估值与管线兑现仍存分歧。临近10月29日财报披露时点，资金更关注业绩兑现与新药管线进展。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.